Tempus AI

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Tempus AI sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 8 currently recruiting 1 completed early-phase tilt top decile by trial count

Tempus AI: 13 sponsored US clinical trials, 8 recruiting.

Tempus AI sponsors 13 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 2 trials.

Top-decile sponsor footprint

Tempus AI ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

13 total, page 1 of 1

RECRUITING

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

NCT07154823
RECRUITING

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies

NCT07211178
RECRUITING

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

NCT06163534
RECRUITING

TEMPUS ARIES: A Biobank Registry Platform Study in Oncology

NCT06207032
RECRUITING

Umbrella Study for Analysis of Data Related to Patients With Cancer

NCT06018753
RECRUITING

Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study

NCT05257551
RECRUITING

GEMINI-NSCLC: NSCLC Biomarker Study

NCT05236114
RECRUITING

Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

NCT05234177
ACTIVE NOT RECRUITING NA

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

NCT06911632
ACTIVE NOT RECRUITING NA

Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease

NCT05442203
ACTIVE NOT RECRUITING

Tempus Priority Study: A Pan-tumor Observational Study

NCT05179824
COMPLETED NA

Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform

NCT06099665
TERMINATED Phase 2

Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors

NCT05169437

Phase Distribution

PhaseTrial count
Phase 2 1

Therapeutic Areas

Breast Cancer 2
Cancer 2
Cancer of Liver 1
Structural Heart Disease 1
Interstitial Lung Disease (ILD) 1
HR Positive/HER-2 Negative Breast Cancer 1
Acute Myeloid Leukaemia (AML) 1
Peritoneal Cancer 1
Aortic Valve Stenosis 1
Early Stage Breast Cancer 1

What is open in the Tempus AI pipeline

8 recruiting of 13 indexed (62% open); 1 completed (8%).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Tempus AI: open-pipeline peers nationwide

Peers matched on 13 registered trials and 62% open enrollment, not the therapeutic-area sidebar.

Tempus AI sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 681012141618 0%20%40%60%80% Total trials Recruiting share Tempus AIAdaptimmuneAgennixAkili Interactive LabsAlumisKrystal BiotechCanadian Cancer Trials GroupCellSight TechnologiesCook Children's Health Care System
Tempus AI sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Tempus AI sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 62% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Tempus AI page

13 registered trials is a research-attention snapshot, not an endorsement of Tempus AI or any single study.

  • 8 of Tempus AI's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Tempus AI studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Tempus AI pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.